Stock Code: 002653.SZ
Home
News
Innovation
Pipeline R&D Platforms
Products
Product List Product Topics Pharmacovigilance
Investors
Stock Information Public Announcements Market Data Q&A Investor Hotline
Join Us
Talent Philosophy Careers
About Haisco
About Us Business Presence
Contact Us

EN

CN EN

EN

CN EN
Stock code: 002653.SZ

Stock code: 002653.SZ

Home
News
Innovation
Pipeline R&D Platforms
Products
Product List Product Topics Pharmacovigilance
Investors
Stock Information Company Announcements Market Data Q&A Investor Hotline
Join Us
Talent Philosophy Careers
About Haisco
About Us Business Presence
Contact Us
GLOBAL
English China
About Haisco
About Haisco

 Haisco Pharmaceutical Group is an international pharmaceutical enterprise integrating R&D, production, and sales (Stock Code: 002653.SZ), focusing on five major therapeutic areas: Anesthesia and Analgesia, Chronic Metabolic Diseases, Respiratory Disease, Autoimmune Disease, and Oncology.
Since its establishment in 2000, the Group has adhered to the "Innovation" and "Internationalization" strategy proposed by its founder and Chairman, Mr. Wang Junmin. It has established a presence across Liaoning, Sichuan, and Tibet, with 5 modern pharmaceutical manufacturing bases, over 30 production lines, and more than 6000 employees, including nearly 1000 R&D professionals.
The Group has over 46 marketed drugs, with 5 Class 1 innovative drugs developed in China and included 4 in the National Basic Medical Insurance Catalog, among which Ciprofol Injection was approved for marketing by the U.S. FDA on May 30, 2026. In 2025, the Group‘s operating revenue reached RMB 4.388 billion, with sales of innovative drugs growing by over 50%, and R&D investment accounting for more than 25% of revenue. As of 2026, the market capitalization has grown to over RMB 80 billion, with 1285 patent applications filed and 428 patents granted.

Number of employees in the company

Researchers in various fields of the R&D center

Current drugs available for sale

Authorized patent obtained
Corporate spirit
Corporate spirit
Innovation

Haisco people must dare to break conventions, continuously innovate and create, and explore new technologies, new methods, and new paths.

Integrity

In their work, Haisco people uphold moral bottom lines and comply with laws and regulations.

Pragmatism

Proceed from reality, keep a close eye on goals, work steadily, and implement every task down to the last detail, one step at a time.

Efficiency

Rapidly and effectively implement corporate strategies and goals, pursue high performance, high efficiency, and high returns, and collaborate with each other to create synergistic benefits where 1+1>2.

Enterprise Vision
Enterprise Vision
Corporate Slogan:

mprove patients' quality of life and safeguard human physical and mental health.

"To become the most trusted international pharmaceutical enterprise" is the convergence of Haisco Group's strategy and culture, and the dream and goal that inspire the potential of all Haisco people.

Corporate values
Corporate values
Sharing Value with Strivers

The future of Haisco is a future of continuously paying tribute to strivers, and a future of tilting opportunities and resources toward strivers. By evaluating and affirming the value created by "strivers," we grant them ample incentive rewards and provide them with a more competitive platform.

Corporate promotional video
Deep cultivation Medical Innovation
Moving steadily towards the most trusted international pharmaceutical company
2026.08
8.25
A preclinical self-exempt innovative drug independently developed by Haisi Cisco has reached an exclusive overseas license with a potential value of more than 1.5 billion US dollars.
2026.07
7.09
Polyene Phosphatidylcholine Injection Enters New National Base List
7.12
Haisco ranked 69th in the “Top 100 Main Income of China's Pharmaceutical Industry”
7.23
National Class 1 Innovative Drug Spraxopan Succinate Tablets (Yucopan;HSK39297) was approved for listing through priority review
7.31
Haisco won two honors: “2026 Medical Technology Innovation Award” and “2026 Chemical Pharmaceutical Influential Enterprise”
2026.06
6.01
China's Class 1 Intravenous Anesthesia Innovative Drug Cyclophenol Approved by the US FDA
6.02
Haisco and Eli Lilly reach first cooperation of up to $3.054 billion
6.09
Haisco (Liaoning) was awarded the provincial advanced intelligent factory in 2026
6.16
The first media day of Haisco Pharmaceutical Group was held in Chengdu, Sichuan, to explore the future of innovative drugs in China
6.23
Haisco and Nuvectis Sign Licensing Agreement for Two Small Molecule New Drugs
6.25
Haisco was shortlisted as the first step in the “Top 100 Chinese Pharmaceutical Innovation Enterprises”
6.28
Haisco was selected as one of the “Top 100 Comprehensive Strengths of Drug R&D in 2026” and “Top 100 Comprehensive Strengths of Chemical Drug R&D in 2026”, ranking 22nd in the Top 100 Comprehensive Strengths of Drug R&D, and ranking 7th in the country in the strength of Chemical Drug R&D.
2026.05
5.15
Carry out the “5.15 National Investor Protection Publicity Day” in 2026
2026.04
4.13
Up to $745 million in licensing fees for the Nav1.8 Inhibitor License Agreement between Haisco and AbbVie, USA
4.20
The Academic Exchange Meeting on the Frontiers of Chinese and Foreign Pharmaceutical Sciences hosted by Haisco was held in Shanghai
4.21
Phase III Registered Study of Cligabarin in the Treatment of Central Neuropathic Pain, presented at the annual meeting of the American Academy of Neurology (aan) as the latest breakthrough oral report
2026.01
1.12
Global licensed AirNexis for Haisco HSK39004 exceeds US $1 billion
2025.09
09.24
Haisco won the “China Innovative Pharmaceutical Decade Honor List - Industry Leading Pharmaceutical Enterprises”
2025.02
02.10
The annual evaluation and recognition meeting of Haisco Pharmaceutical Group “Forward to New Life” Group was held
2024.12
12.19
Haisco launched the “Love on the Road, Warm Together” charity activity
2024.11
11.04
Haisco won four awards: “Top 50 Independent Innovation Enterprises”, “Top 100 Pharmaceutical Commercial Revenue Enterprises”, “Top 100 Pharmaceutical Industry Revenue Enterprises” and “Law Abiding and Honest Enterprises”
2024.09
09.01
Haisco Launches “Financial Consumer Rights Protection Education and Publicity Month” Campaign
2024.07
07.20
Haisco Pharmaceutical Group was listed in the “2024 China Innovative Pharmaceutical Enterprises” list.
2024.06
06.24
Biweekly ultra-long-acting oral hypoglycemic drug Benchampine ® Coagliptin tablets were officially approved, opening a new era of diabetes treatment!
06.27
Haisco Pharmaceutical Group was listed in the “Top 100 Sinochem Pharmaceutical Enterprises in 2023”.
06.27
Haisco Pharmaceutical Group received three awards, including the “Dingxin Award - Excellence in Learning and Development Team Award”.
2024.05
05.20
The first new drug for the treatment of DPNP in mainland China, Simenon ® Cligabalin Benzenesulfonate Capsules, was approved for marketing.
2023.11
11.17
Haisco Pharmaceutical Group won the honorary title of “Best Industrial Enterprise of China's Pharmaceutical R&D Product Line in 2023”.
11.20
Heiskel signed a HSK31858 tablet licensing agreement with the Chiesi Group in Italy.
11.24
Haisco Pharmaceutical Group won the second prize in the “China (Xiaoshan) Biomedical Industry High-value Patent Cultivation Competition”.
2023.09
09.13
Haisco's innovative drug HSK36357 capsule IND was accepted.
09.14
Haisco's innovative drug HSK16149 capsule “Postherpetic Neuralgia” indication NDA was accepted.
09.18
The first subject in the Phase I clinical trial of Haisco's innovative drug HSK21542 tablets was enrolled.
2023.07
07.07
Haisco won four awards in the “Most Influential List of China's Pharmaceutical Industry 2022-2023”.
2023.06
06.05
Haisco Innovations HSK34890 IND was accepted.
06.26
The ADA conference on two innovative drug research results in the endocrinology field of Haisco was released.
2023.03
03.09
The first subject enrolled in the Phase I clinical trial of Haisco's innovative drug HSK40118 tablets.
03.28
Haisco's innovative drug HSK38008 oral formulation IND was accepted.
2023.01
01.10
Haisco's innovative drug HSK40118 tablets IND was accepted.
01.30
Haisco's long-acting DPP-4 inhibitor HSK7653 tablet NDA was accepted.
01.31
Haisco's innovative drug HSK38008 oral formulation IND was accepted.
2022.12
12.08
The first subject in the Phase II clinical trial of Haisco's innovative drug HSK31858 tablets was enrolled.
2022.11
11.09
Haisco HSK16149 capsule “diabetic peripheral neuralgia” indication NDA was accepted.
11.17
The phase II clinical trial of Haisco's innovative drug HSK31858 received ethical approval.
2022.07
07.08
Compound amino acid (18AA)/glucose (15%) electrolyte injection exclusively passed the generic drug consistency evaluation.
07.14
The company's products are planned to select the seventh batch of national drug centralized procurement.
07.15
Cyclophenol injection receives a sedation Drug Registration Certificate during intensive care.
07.19
Haisco Pharmaceutical Group Co., Ltd. won the title of “2021 Top 100 Sinochem Pharmaceutical Enterprises” Top 100 Enterprises.
2022.05
05.26
Polyprazine granules were evaluated for consistency with generic drugs.
2022.04
04.11
HSK36273 for innovative drug injection received the Notice of Approval for Drug Clinical Trial.
04.18
A US clinical trial of the innovative drug HSK29116 was licensed.
04.20
Fat emulsion amino acid (17) glucose (11%) injection passed the generic drug consistency evaluation.
2022.03
03.03
Group Companies and Aquestive Therapeutics, Inc. Sign a licensing and supply agreement for riluzole oral membrane EXSERVAN™ for the treatment of amyotrophic lateral sclerosis.
03.25
Cyclophenol injection received the Notice of Approval of Drug Supplement Application.
2022.02
02.08
The innovative drug HSK31679 tablets received the Notice of Approval for Drug Clinical Trials.
02.08
The innovative drug HSK31858 tablets received the Notice of Approval for Drug Clinical Trials.
02.24
Cyclophenol injection obtains a Drug Registration Certificate for the induction and maintenance of general anesthesia.
2021.12
12.06
Cyclophenol injections are included in the national health insurance catalogue.
12.14
The innovative drug cyclophenol injection obtained a sedation “Drug Registration Certificate” during bronchoscopy.
12.28
Haisco Pharmaceutical Group won the honorary title of “China Innovative Pharmaceutical Enterprise in 2021”
2021.10
10.13
Haisco Pharmaceutical Group was listed in the “2021 List of Excellent Enterprises and Excellent Product Brands in China's Chemical and Pharmaceutical Industry”.
10.18
Haisco Pharmaceutical Group won five awards such as the 2020 China Top 100 Pharmaceutical Businesses.
2021.09
09.01
Compound amino acid (15AA- Ⅱ)/glucose (10%) electrolyte injection obtained the Drug Registration Certificate.
09.09
Cefmetazole sodium for injection was evaluated for consistency with generic drugs.
09.10
HISCO Pharmaceutical Group was awarded the “Listed Company's 2020 Annual Report Performance Presentation Meeting Excellent Practice Case”.
09.14
The company signed a cooperation agreement for the first innovative drug candidate, Lorecivivint.
09.16
Propofol Medium/Long Chain Fat Emulsion Injection obtained a Drug Registration Certificate.
09.24
Cefotian hydrochloride for injection was evaluated for consistency by generic drug.
2021.08
08.02
The innovative drug HSK16149 capsule was approved to carry out a phase II clinical trial of “adjuvant opioid analgesia”.
08.02
Haisco Pharmaceutical Group won the honorary title of “Top 100 Enterprises in China's Pharmaceutical Industry in 2020” and “Best Industrial Enterprises in China's Pharmaceutical R&D Product Line in 2021”.
08.03
The innovative drug HSK21542 injection was approved to carry out the phase II clinical trial of “itching in liver disease”.
08.06
For you to “yu” your presence - to help Henan, Haisko people in action.
2021.07
07.08
The innovative drug cyclophenol injection Phase III clinical trial has obtained ethical approval.
07.22
Compound amino acid injection (18AA- Ⅶ) passed the generic drug consistency evaluation.
07.22
Fat Emulsion Amino Acid (17) Glucose (11%) Injection New Drug Specification Approved.
07.27
Perindopril indapamide tablets received a Drug Registration Certificate.
07.31
“Yu” You donated rescue drugs to help Henan at Haisco Pharmaceutical Group.
2021.06
06.15
The signing ceremony of the strategic cooperation between Haisco Pharmaceutical Group and Shanghai Yunyun Health was successfully held.
2021.05
05.07
Medium/Long Chain Fat Emulsion Injection (C6-24) passed the generic drug consistency evaluation.
2021.04
04.06
Methylprednisolone sodium succinate for injection was evaluated for consistency with generic drugs.
04.07
The clinical trial of the innovative drug HSK29116 powder was approved.
2021.03
03.01
Group Companies and Starton Therapeutics Inc. Sign the olanzapine transdermal patch cooperation agreement.
03.29
The innovative drug HSK21542 injection Phase III clinical trial protocol was approved by CDE.
03.29
Avanafil received a Drug Registration Certificate.
2021.02
02.01
Ticagrelor tablets received a Drug Registration Certificate.
02.03
The innovative drug cyclophenol injection obtained the Drug Registration Certificate of General Anesthesia Induction.
02.03
Emtricitabine tenofovir tablets received a Drug Registration Certificate.
02.07
“Break the game, know how to take responsibility, and innovate butterfly change” Haisco's 2021 marketing center annual meeting was successfully held.
02.25
Palonosetron Hydrochloride Injection was evaluated for generic drug consistency.
2021.01
01.08
The US Phase III clinical trial application for the innovative drug HSK-3486 was approved by the FDA.
01.20
Fat emulsion amino acid (17) glucose (11%) injection passed the generic drug consistency evaluation.
01.26
Fat emulsion amino acid (17) glucose (11%) injection passed the generic drug consistency evaluation.
01.29
Esomeprazole sodium for injection was evaluated for consistency with generic drugs.
2020.12
12.02
The innovative drug FTP-198 was approved for clinical trials.
12.17
The innovative drug HSK3486 Emulsion Injection was approved for a Phase III clinical trial of sedation during intensive care unit (ICU).
12.18
The innovative drug Cyclophenol Injection received a Drug Registration Certificate.
12.22
Fonda Deca Injection obtained the Drug Registration Certificate.
12.24
Haisco Pharmaceutical Group won the list of China Innovative Pharmaceutical Enterprises in 2020.
2020.11
11.30
Pramipexol hydrochloride sustained-release tablets received a Drug Registration Certificate.
2020.10
10.12
The innovative drug HSK3486 Emulsion Injection was approved for Phase III clinical trial of “general anesthesia maintenance”.
10.13
Perindopril tert-butylamine tablets received a Drug Registration Certificate.
10.16
Haisco won three honorary titles of “2020 China Chemical and Pharmaceutical Industry Excellent Enterprises and Excellent Product Brands List”: “2020 China Chemical and Pharmaceutical Industry Industrial Enterprises Comprehensive Strength Top 100” (39th), “China Chemical and Pharmaceutical Industry Innovative Excellent Enterprise Brand” (11th), and “China Chemical and Pharmaceutical Industry Integration Promotion Excellent Enterprise Brand” (8th).The company's products, Nomefon Hydrochloride Injection and Lepan ® Flupentixol Melitracen Tablets, were awarded the title of “Excellent Product Brand of Nervous and Psychiatric Systems in China's Chemical and Pharmaceutical Industry” (ranked 21st and 25th respectively);Jiesu ® Compound Amino Acid Injection (18AA- Ⅶ) won the title of “Excellent Product Brand for Regulating Water, Electrolyte, Acid-Base Balance, Minerals and Nutritional Supplements in China's Chemical and Pharmaceutical Industry” (12th place);Ribiflu ® Dorasetron Mesylate Injection was awarded the title of Excellent Product Brand in Anti-tumor and Immunomodulation in the Chinese Chemical and Pharmaceutical Industry (9th).
2020.09
09.03
Haisco won the honorary titles of “Top 100 Enterprises in China's Pharmaceutical Industry in 2019”, “Best Industrial Enterprise in China's Pharmaceutical R&D Product Line in 2020” and “Excellent Project of China's Pharmaceutical Corporate Social Responsibility”.
09.16
The innovative drug HSK16149 capsule was approved for Phase II/III clinical study.
2020.08
08.12
Haisco was awarded four honorary titles in the “2019 China Pharmaceutical Industry Most Influential List”: “2019 China Pharmaceutical Industry Top 100”, “2019 China Pharmaceutical Business Top 100”, “2019 China Pharmaceutical Industry Top 50 Growth”, and “2019 Integrity and Law Abiding Enterprises”.
08.18
The innovative drug HSK7653 was approved for Phase III clinical research;Caspofungin Acetate for Injection received a Drug Registration Certificate.
2020.07
07.17
In order to promote the clinical research of the Company's products overseas, Haisco Pharmaceutical Pte. Ltd., a wholly-owned subsidiary of Haisco Pharmaceutical Holdings Group Limited, was established.
2020.06
06.29
Si Shu Ning ® Cyclophenol Emulsion Injection received the “Supplementary Information Notice” issued by the State Drug Administration.
2020.05
05.14
HSK21542 Injection is approved for clinical trials intended for the treatment of pruritus.
2020.04
04.08
The Group established the registration of Haisco Pharmaceutical Holdings Group Limited in Cayman to accelerate the company's internationalization process and enhance the company's overseas market influence.
04.21
Haisco pharmaceutical holdings group limited set up Haisco Innovative Pharmaceutical Pte. Ltd. in Singapore and the United States to promote the clinical research of the company's products overseas., two wholly owned subsidiaries of Haisco-USA Pharmaceuticals, Inc.
2020.03
03.25
Haisco Pharmaceutical Group established Haisco Holdings PTE.LTD, a wholly-owned grandchild in Singapore, to promote overseas clinical research, accelerate the company's internationalization process, and enhance the company's overseas market influence.
03.30
Sichuan Haisco Pharmaceutical Co., Ltd. received the Clinical Trial Notice recently in cooperation with Estevei Pharmaceutical Company of Spain for the product dabigatran ester capsule (oral direct anticoagulant drug).
2020.02
02.20
Cyclophenol emulsion injection was included in the “Publicity of Proposed Priority Evaluation Varieties” list by the Drug Evaluation Center of the State Drug Administration.
2020.01
01.03
Haisco Pharmaceutical Group won the title of “2018 (First) 100 Outstanding National Private Pharmaceutical Commercial Circulation Enterprises”.
2019.12
12.05
Liaoning Haisco Pharmaceutical Co., Ltd. 's large-volume injection (including multi-layer co-extruded infusion bags) (workshop 601) meets the requirements of the “Good Manufacturing Practice” of the People's Republic of China, and recently obtained the “Pharmaceutical GMP Certificate” of the People's Republic of China issued by the Liaoning Provincial Drug Administration.
12.23
Liaoning Haisco Pharmaceutical Co., Ltd. obtained the drug registration approval for compound amino acid injection (18AA-IX).
12.25
The company has obtained clinical trial permission for HSK21542 injection, an analgesic drug with independent intellectual property rights.
12.31
Haisco Pharmaceutical Group is rated AAA by the pharmaceutical industry for corporate credit ratings.
2019.11
11.15
Haisco won the “Technology Innovation Award” in the “70th Anniversary of New China · Chinese Medical and Health Enterprise Merit Unit” selection activity.
11.28
The company's exclusive product, Arginine Glutamic Acid Injection, was included in the “Negotiated Drugs during the Agreement Period” in the “Medical Insurance Catalogue”.
2019.10
10.09
Haisco won the honorary titles of “Pride Enterprise in the Pharmaceutical Industry for the 70th Anniversary of the Founding of New China” and “Top 100 Pharmaceutical Innovation Enterprises in China in 2019”.
10.10
Haisco won the titles of “2019 China Chemical and Pharmaceutical Industry Enterprise Comprehensive Strength Top 100”, “2019 China Chemical and Pharmaceutical Industry Innovation Excellent Enterprise Brand” and “2019 China Chemical and Pharmaceutical Industry Integration Promotion Excellent Enterprise Brand”.
2019.09
09.14
The company signed a cooperation agreement for the first innovative drug candidate, Lorecivivint.
2019.08
08.09
Sichuan Haisco Pharmaceutical Co., Ltd. obtained the “Intellectual Property Management System Certification”.
08.21
The company's intravenous anesthetic HSK3486 emulsion injection with independent intellectual property rights was included in the “Publicity List of Proposed Priority Review Varieties” by the Drug Evaluation Center of the State Drug Administration.
2019.07
07.03
Sichuan Haisco Pharmaceutical Co., Ltd. signed a cooperation agreement with Glenmark Pharmaceuticals Limited in India on aprepitant capsules (effective prevention of vomiting caused by chemotherapy), which Haisco registered and applied for and sold in mainland China.
07.13
Silara Medtech GmbH, a wholly-owned subsidiary of Hiscone Pharmaceutical Group, was established in Frankfurt, Germany to expand its sales channels.
07.15
Haisco was successfully selected as a sub-list of the “2018 Top 100 Chinese Pharmaceutical Industry Series List”, “2018 Top 100 Chinese Chemical Pharmaceutical Enterprises List”, and won the title of “2018 Top 100 Chinese Chemical Pharmaceutical Enterprises List” Top 100 Enterprises.
07.24
The 2019 Mid-Year General Meeting of the Haisco Marketing Center was successfully held.
2019.06
06.03
Haisco won five awards in the “2018 Most Influential List of China's Pharmaceutical Industry”: “2018 Top 100 Pharmaceutical Businesses”, “2018 Top 20 R&D of China Pharmaceutical Group”, “2018 Law Abiding and Honest Enterprises”, “2018 Top 50 Enterprises in the Growth of China's Pharmaceutical Industry”, and “2018 Top 100 Enterprises in China's Pharmaceutical Industry”.
06.04
Haisco Pharmaceutical Group established a wholly-owned subsidiary in Naidong District, Shannan City, Tibet, to prepare for the establishment of professional production lines such as solid preparations, Chinese medicine slices, and nutritional foods to enhance the company's market competitiveness and sustainable development capabilities.
2019.04
04.02
Sichuan Haisco Pharmaceutical Co., Ltd. invested $6 million in eXIthera in the United States and obtained an exclusive license for its product EP-7041 (anticoagulant and antithrombotic) in mainland China for a period of 10 years.
04.10
Sichuan Haisco Pharmaceutical Co., Ltd. received the “Drug Registration Approval Document” of Tenofovir Dipivoxil Fumarate Tablets.
04.30
Haisco Pharmaceutical (Australia) Pty Ltd, a wholly-owned grandson of Haisco Pharmaceutical Group, established in New South Wales, Australia, to shorten government approvals for the clinical trial phase of new drug projects and increase global acceptance of clinical data.
2019.03
03.19
The company submitted a Pre-IND meeting (pre-clinical consultation meeting) request for the intravenous anesthetic HSK-3486 emulsion with independent intellectual property rights to the US FDA and received an email confirmation.
2019.02
02.25
Sichuan Haisco Pharmaceutical Co., Ltd. received the “Drug Supplement Application Approval” of Flupentixol Tonne Melitracen Tablets. This variety was the first to pass the quality and efficacy consistency evaluation of generic drugs.
2019.01
01.19
The HC-1119 Clinical Researchers Meeting of “Walking with Life and Striving Together” was successfully held.
01.24
“Change creates opportunities and starts with struggle” - The 2018 Annual General Meeting of Haisco Marketing Center and the Opening Meeting of Haisco's Marketing Platform Construction were successfully held.
01.25
You can look forward to the future - the 2019 theme annual meeting of the Haisco Pharmaceutical Group was successfully held.
01.29
Sichuan Haisco Pharmaceutical Co., Ltd. received a review opinion that the oral diabetes drug HSK7653 can enter the phase Ⅱ α clinical study.
01.31
Sichuan Haisco Pharmaceutical Co., Ltd. received an approval letter for the Phase III clinical study of the prostate cancer drug HC-1119 softgel.
2018.12
12.20
Haisco obtained the “two integration management system” evaluation certificate.
2018.11
11.05
Haisco's heavyweight variety HSK3486 and Dolasetron joined hands to attend the annual meeting of the Chinese Medical Association on anesthesia.
2018.10
10.09
Haisco was approved to set up a station unit for the “National Postdoctoral Research Workstation”.
10.12
Haisco held the Standards Promotion Meeting of the Code for the Management of Intellectual Property Rights.
10.13
Haisco successfully participated in the American Anesthesia Annual Conference with the independently developed innovative drug HSK3486 and updated the research results.
10.16
Haisco Pharmaceutical Group won two awards at the 2018 China Chemical and Pharmaceutical Industry Annual Summit.
10.24
Chuanhai was awarded the title of “Chengdu City (First Batch) Demonstration Enterprise for the Integration of Two Industries”.
2018.07
07.23
“Strong conviction, clear goals, and light loading” - The 2018 Semi-Annual Plenary Meeting of the Haisco Marketing Center was successfully held.
2018.06
06.02
The results of the HSK3486 clinical phase I and II studies were officially released at the European Anesthesia Annual Meeting.
06.24
Haisco was named one of the five most influential awards in China's pharmaceutical industry in 2017.
2018.05
05.09
Haisco won the honorary title of “Advanced Private Enterprise” in the Precision Poverty Alleviation Action of “Hundred Enterprises and Hundred Villages” in Tibet Autonomous Region.
05.15
Haisco's third drug in 2018, palonosetron hydrochloride injection, was approved.
2018.04
04.19
“Unified thinking, unified goal and unified action” - The first quarterly meeting of the Marketing Center in 2018 was successfully held.
2017.12
12.02
Haisco participated in the “Love Without Boundaries” 2017 Charity Dinner.
12.27
New Situation New Marketing New Journey - The Group's Marketing Center Sales Annual Meeting was successfully held in 2017.
2017.11
11.07
Haisco Guangyu ® Compound Vitamins for Injection (3) was included in the 2017 “China Pharmaceutical and Brand Rui List”.
11.14
The Group obtained the clinical trial approval of inda troglonium maleate inhalation powder aerosol.
11.14
The Group won the title of “Excellent Enterprise and Excellent Product Brand in China's Chemical and Pharmaceutical Industry in 2017”.
2017.10
10.12
The leaders of the Provincial Human Resources and Social Security Department visited the company to conduct research and guide the work of the post-doctoral innovation practice base.
10.21
The Group was awarded the “Learning Organization” award at the 2017 Global Entrepreneur of the Year Summit.
2017.08
08.08
Haisco Pharmaceutical Group and Yide Biotechnology signed a strategic cooperation agreement to jointly explore the field of treatment of chronic respiratory diseases.
2017.07
07.07
Haisco obtained a clinical trial approval for fluticasone furoate nasal spray.
2017.06
06.05
The group company won four honorary titles such as “2016 Top 20 Non-Public Enterprises in Revenue” in Tibet.
06.07
The launch meeting for the integration of HISCO and HISCO was successfully held.
06.20
Haisco won three awards in the “2016 China Pharmaceutical Industry Most Influential List”.
06.28
Haisco was rated A in the 2016 annual information disclosure assessment of the Shenzhen Stock Exchange.
2017.05
05.23
Haisco created a dual channel for the development of R&D talents, and the 2016-2017 professional and technical grade evaluation certificate awarding ceremony was successfully held.
2017.03
03..09
The first phase of the SAP ERP project of the group “Operation Icebreaker” was successfully launched.
2017.01
01.16
The practice of change wins the future - the 2016 Marketing Center Sales Annual Meeting was successfully held.
2016.12
12.01
The opening ceremony of Haisco Xinchuan Innovation Technology Park project was successfully held.
12.02
The seminar on strategic cooperation between Haisco and Sinopharm Holdings was successfully held in Kunming. The two sides will work together to focus on the terminal together with distributors, so as to achieve the purpose of innovating cooperation channels, expanding market share and multiple benefits.
2016.10
10.24
Sichuan Haisco Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the Group, used its own funds of RMB 33,454,000 to make an equity investment in Chengdu Haichuang Pharmaceutical Co., Ltd., and obtained the exclusive patent license for HC-1119, a prostate cancer drug developed by Haichuang Pharmaceutical's patented technology, and various pharmaceutical preparations with it as an active ingredient in China.
2016.08
08.10
Obtain the drug registration approval for Cinepazide Maleate Injection.
08.25
The launch meeting of the Haisco ERP project was held.
2016.07
07.27
The inaugural conference of Haisco University was held in Wenjiang.
2016.05
05.13
Haisco and its wholly owned subsidiaries and MaveriX Oncology, Inc. The company signed an agreement to make an equity investment in MaveriX and obtained the exclusive patent license for MaveriX's world's first innovative tumor-targeting gemcitabine-releasing prodrug MVX series compound in China (including Hong Kong, Macau, Taiwan).
2016.02
02.25
Haisco Group acquired a stake in Microbion Corporation of the United States and obtained the Chinese licensing rights for its innovative drug patents.
2015.11
11.07
Haisco was awarded the honorary title of “2015 China Chemical and Pharmaceutical Industry Growth Excellent Enterprise Brand”.
2015.10
10.28
The groundbreaking ceremony for Shenyang Haisco Pharmaceutical Co., Ltd. was successfully held.
2015.04
04.14
Haisco was listed as one of China's Top 50 Pharmaceutical Growth Enterprises.
2014.08
08.20
Haisco Group was awarded the top 20 competitiveness of listed Chinese pharmaceutical companies in 2014.
2014.04
04.10
Haisco Group was awarded the “2013 China Pharmaceutical Industry Growth Top 50” and the “Most Influential Top 100”.
2014.03
03.17
Obtain drug registration approval for lupatadine fumarate tablets.
2014.01
01.06
Forbes launched the “China's Most Potential SMEs List”.Among the top 100 companies with listing potential in China, Haisco Group ranked third.
2013.12
12.10
Haisco's innovative drug research and development team was selected as the innovation team of the provincial “Thousand Talents Program”.
2013.08
08.07
Obtain drug registration approval for methylprednisolone sodium succinate for injection.
2013.05
05.20
Obtain Drug Registration Approval for Compound Vitamins for Injection (3).
2013.04
04.23
Obtain drug registration approval for entecavir capsules.
2012.05
05.15
Drug registration approval for manidipine hydrochloride was obtained.
2012.03
03.01
Famous American scientist Deng Bingchu joined HISCO, marking the arrival of HISCO's absorption of high-end talents.
2012.01
01.17
Haisco Pharmaceutical Group is listed on the Shenzhen Stock Exchange.
2011.10
10.21
Liaohai Haisco Pharmaceutical Co., Ltd. obtained a production approval for cefoperazone sodium tazobactam sodium for injection.
2011.08
08.15
Liaohai Haisco Pharmaceutical Co., Ltd. obtained a production approval for cefoperazone sodium tazobactam sodium for injection.
2011.07
07.18
Liaohai Haisco Pharmaceutical Co., Ltd. obtained the new drug certificate and production approval for Dorasetron Mesylate Injection.
07.20
Sichuan Haisco Pharmaceutical Co., Ltd. passed the dynamic verification of BHA, BHT, and gentanyl ethanolamine by the National Food and Drug Administration Drug Certification Management Center.
2011.04
04.19
The Beijing Registration Department was established.
2011.02
02.18
The company signed a land use agreement for Sichuan Haimeishan Branch to expand production scale.
2010.12
12.25
Haisco Group officially occupies the new office building on the campus.
2010.07
07.29
Sichuan Haisco Co., Ltd. raw materials workshop 2 passed GMP certification.
2010.03
03.20
Haisco has formulated a three-year human resources plan based on the current situation of the Group, and proposed that 2010 is the slogan of the “Year of System Construction”. The Group's market-oriented functional construction and business management with business as the main line have been continuously strengthened.
2010.01
01.12
In order to adapt to the changes in the external environment of the company and the needs of the corporate development strategy, the company made major adjustments in the organizational system at the beginning of the year and established the Wenjiang Park of the Haisco Group.
2009.12
12.09
The company obtained a patent license for the invention of sodium fusidate for injection.
2009.06
06.17
Liaoning Haisco's first product, Nomefon Hydrochloride Injection, was officially put into production, marking the company's formal entry into the pharmaceutical industry integrating production, R&D and sales.
2009.05
05.20
The company obtained the invention patent license for silver multi-injection.
2009.03
03.12
The water needle workshop of Liaoning Haisco Pharmaceutical Co., Ltd. obtained GMP certification.
2009.02
02.18
Liaoning Haisco Pharmaceutical Co., Ltd. has obtained the registration approval for cefodizime sodium for injection.
2009.01
01.11
Four varieties of APIs from workshop 1 of Sichuan Haisco Pharmaceutical Co., Ltd. have passed GMP certification.
2008.11
11.07
Sichuan Haisco Pharmaceutical Co., Ltd. has obtained drug registration approval documents for polyene phosphatidylcholine drug substance, right panthenol drug substance, fusidic acid sodium drug substance, and ropivacaine hydrochloride drug substance.
2008.09
09.22
Liaoning Haisco Pharmaceutical Co., Ltd. obtained the new drug certificate of nalmefen hydrochloride and the new drug certificate of nalmefen hydrochloride injection and the drug registration approval documents.
2008.01
01.19
Sichuan Haisco Pharmaceutical Co., Ltd. began the infrastructure construction of the plant.
2007.12
12.11
The company acquired Tibet Kangxin Pharmaceutical Co., Ltd., laying the groundwork for the development into a group company.
2007.04
04.09
Sichuan Haisco Pharmaceutical Co., Ltd. was formally established.
2006.12
12.10
The first phase of the 14-month construction of Liaoning Haisco Pharmaceutical Co., Ltd. was completed, and preparations for the workshop GMP certification began.
2006.06
06.16
The company has obtained a new drug certificate for mixed sugar electrolyte injection.
2005.12
12.05
Shenyang Albatross Pharmaceutical Co., Ltd. established
12.09
Sichuan Kangdeli Pharmaceutical Co., Ltd. was established
12.15
The company obtained new drug certificates for fat-soluble vitamin (I) for injection and fat-soluble vitamin (II) for injection
2005.10
10.01
Liaoning Haisco Pharmaceutical Co., Ltd. laid the foundation and began construction.
10.19
The company obtained a new drug certificate for sodium fusidate.
2005.09
09.22
The company obtained a new drug certificate for fructose sodium chloride injection.
09.26
The company obtained a new drug certificate for aminophenol methionine capsules.
2005.07
07.29
The company obtained the new drug certificate of Racitaxel oral disintegration tablets.
2005.05
05.19
Liaoning Haisco Pharmaceutical Co., Ltd. was formally incorporated.
2005.02
02.06
The company obtained the new drug certificate of converted sugar electrolyte injection, further establishing the company's core competitive advantage in the field of parenteral nutrition.
2004.11
11.26
Obtain a New Drug Certificate for Enoxacin Gluconate Injection.
2004.10
10.29
Obtain a new drug certificate for Pazufloxacin Mesylate, Pazufloxacin Mesylate Sodium Chloride Injection.
2004.01
01.08
The company's independently developed fist product, Resistance Conversion Sugar Injection, has obtained a new drug certificate. This product fills the gap in the domestic market for organism stress insulin resistance energy therapy, which has cross-age significance in clinical treatment, and also marks the company's leading level in the research and development of high-end nutritional therapies.
2003.11
11.26
The company has made major breakthroughs in technology and obtained new drug certificates for fructose and fructose injection, marking the company's achievements in the field of new drug research and development.
2000.07
07.18
Haisco's predecessor, Chengdu Borui Pharmaceutical Technology Development Co., Ltd., was officially incorporated and began to focus on new drug research and development, igniting the fire of entrepreneurship.
Deep cultivation <span> Medical Innovation</span><br>Moving steadily towards the most trusted international pharmaceutical company
Triumph CoronationDiligent and persistent
Each award carries the trust of patients and the industry. Haisco will turn honor into motivation to move forward, with a more rigorous attitude and innovative technology, focusing on fields such as anesthesia and pain relief, and respiration treatments, using reliable medical products to protect every life.
2026
22nd in the top 100 for comprehensive drug research and development capabilities
2026
Ranked 7th in the National Top 100 List of Traditional Chinese Medicine R&D Strength
2026
Top 100 Innovative Pharmaceutical Companies in China
2026
Top 100 Chinese pharmaceutical innovators in “First Tier”
2026
Chinese domestic pharmaceutical companies rank seventh in the number of clinical Phase II and Phase III studies
2026
Liaoning Provincial Advanced Intelligent Factory
2025 Year
Chengdu Emergency Management Office - A Three-Level Standardized Safety Production Enterprise
2025 Year
Best Access Award
2025 Year
Top 100 Chinese pharmaceutical industry enterprises in 2024 (88th place)
2025 Year
Strategic Cooperation Unit of Shanxi Bethune Hospital’s Pharmaceutical Clinical Trial Institution
2025 Year
China Pharmaceutical Industry Information Center - 2025 Excellent Cases of Pharmaceutical R&D Product Line Enterprises in China
2025 Year
China Pharmaceutical Industry Information Center - Social Responsibility of Chinese Pharmaceutical Enterprises
2025 Year
All China Pharmaceutical Industry Chamber of Commerce - 100 Enterprises with Medical Industry Revenue in 2024-2025
2025 Year
All China Pharmaceutical Industry Chamber of Commerce - Law-abiding and Honest Enterprises in the Pharmaceutical Industry for 2024-2025
2025 Year
Full Union Pharmaceutical Industry Chamber of Commerce - Top 50 Enterprises in the Pharmaceutical Industry Growth Rate for 2024-2025
2025 Year
All China Pharmaceutical Industry Chamber of Commerce - Top 50 Enterprises in Independent Innovation of the Pharmaceutical Industry for 2024-2025
2025 Year
All China Pharmaceutical Industry Chamber of Commerce - 100 Private Pharmaceutical Enterprises for 2024-2025 Business Year
2025 Year
2025 Top 100 Chinese Pharmaceutical Innovation Companies - E-Pharmacy Managers
2025 Year
Ranked 55th among the top 100 Sichuan enterprises in technological innovation capacity
2025 Year
Ranked 7 in the top 100 Sichuan enterprises with invention patents
2025 Year
Report on the Development of the Top 100 Sichuan Enterprises with Technological Innovation Capabilities
2025 Year
In 2025, China's pharmaceutical industry had a 69th place in total revenue.
2024
2024’s Innovative Pharmaceutical Companies in China
2024
2023 Annual TOP 100 List of Chinese Pharmaceutical Companies
2024
Dingxin Award - Three honors including the Excellence Learning and Development Team Award
2023
2023 Best Industrial Enterprise in China's Pharmaceutical R&D Product Line
2023
Top 100 Pharmaceutical Business Enterprises, Top 100 Pharmaceutical Manufacturing Enterprises
2023
2022 China’s Innovative Pharmaceutical Companies
2022
2022 Top 100 Chinese Pharmaceutical Innovation Companies
2022
Best Industrial Enterprise in China's Pharmaceutical R&D Product Line
2022
2022 China Pharmaceutical Enterprises Social Responsibility Alliance Excellence Project
2022
2021 Top 100 Chinese Pharmaceutical Companies
2021
2021 Best Industrial Enterprise in China's Pharmaceutical R&D Product Line
2020
80th among the Top 100 Chinese pharmaceutical industries in 2020
2020
2020 Top 100 Chinese Pharmaceutical Companies
2020
Excellent practice cases for the annual report meeting of listed companies in 2020
2020
Pharmaceutical Industry Enterprise Credit Rating Certificate AAA
2020
2020 Chinese innovative pharmaceutical companies
2020
2020 Chinese innovative pharmaceutical companies
2020
2020 Top 100 Chinese Pharmaceutical Innovation Companies
2020
Top 20 Competitive Chinese Pharmaceutical Companies in 2020
2020
Social Welfare Responsibility Award
2020
2020 Chinese Chemical Pharmaceutical Industry Innovative Excellence Enterprise Brand
2020
2020 China Chemical Pharmaceutical Industry Excellence in Integrated Digital and Industrial Development Brand
2020
2020 Top 100 Industrial Enterprises in China's Chemical Pharmaceutical Industry by Comprehensive Strength
2020
2020 Chinese Chemical Pharmaceutical Industry: Excellent Product Brands in Neurological and Mental Systems
2020
2020 Chinese Chemical Pharmaceutical Industry: Outstanding Product Brands in Antitumor and Immunomodulatory Agents
2020
2020 Chinese Chemical Pharmaceutical Industry: Top Products Brands for Regulating Water, Electrolytes and Acid-Base Balance, and Minerals & Nutrient Supplements
2020
2020 Outstanding Social Responsibility Projects of Chinese Pharmaceutical Companies
2020
2020 Best Industrial Enterprise in China's Pharmaceutical R&D Product Line
2019
One Hundred Outstanding Private Pharmaceutical Business Enterprises in the Country
2019
85th on the 2019 Top 100 Industrial Companies List
2019
2019 Top 50 Growing Enterprises in the Chinese Pharmaceutical Industry
2019
Pharmaceutical Industry Enterprise Credit Rating Certificate AAA
2019
2019 Top 100 Chinese Pharmaceutical Innovation Companies
2019
2019 Chinese Chemical Pharmaceutical Industry – Excellent Products in Digestive System Category
2019
2019 China Chemical Pharmaceutical Industry Excellence in Integration of Information and Technology Brands
2019
Top 100 Industrial Enterprises in China's Chemical Pharmaceutical Industry in 2019
2019
2019 Chinese Chemical Pharmaceutical Industry Innovative Excellence Enterprise Brand
2019
2019 Chinese innovative pharmaceutical companies
2019
2019 Top 100 Commercial Enterprises in China's Pharmaceutical Industry
2019
2019 Annual Legal and Integrity Enterprises in the Chinese Pharmaceutical Industry
2019
Top 100 Chinese pharmaceutical industries companies in 2019
2019
Top 100 Chinese pharmaceutical industries companies in 2019
2019
70th Anniversary of the Establishment of the People’s Republic of China · Innovation Technology Award for Meritorious Units of Chinese Medical and Health Enterprises
2019
Enterprise Recognized as a Leader in the Pharmaceutical Industry on the 70th Anniversary of the Founding of New China
2018
Top 20 R&D Companies in China's Pharmaceutical Industry
2018
Top 50 Growing Companies in the Chinese Pharmaceutical Industry
2018
China's pharmaceutical enterprises that abide by laws and maintain integrity
2018
2018 Chinese Top 100 Pharmaceutical Industries List
2018
2018 Top 100 Chinese Pharmaceutical Companies
2018
Person in Private Pharmaceutical Business Expansion
2018
2018 National Top 100 Excellent Private Pharmaceutical Business Enterprises
2018
2018 National Top 100 Excellent Private Pharmaceutical Business Enterprises
2018
2018 National Top 100 Excellent Private Pharmaceutical Business Enterprises
2018
2018 National Top 100 Excellent Private Pharmaceutical Business Enterprises
2018
2018 National Top 100 Excellent Private Pharmaceutical Business Enterprises
2018
2018 National Top 100 Excellent Private Pharmaceutical Business Enterprises
2018
2018 National Top 100 Excellent Private Pharmaceutical Business Enterprises
2018
2018 National Top 100 Excellent Private Pharmaceutical Business Enterprises
2018
2018 National Top 100 Excellent Private Pharmaceutical Business Enterprises
Bear a load Social responsibility
Promote industry and
social development

Haisco actively fulfills its corporate social responsibilities. Since 2008, the group has invested over 36 million yuan in public welfare and charity efforts, which are applied in various dimensions of social responsibility such as disaster relief and rural development. During the COVID-19 pandemic in 2020, Haisco (Sichuan) and Haisco (Liaoning) donated medicines to support Wuhan. Haisco (Liaoning) also donated over 1.686 million doses of treatment medicines worth 3.3 million yuan to the Red Cross Society of the Tibet Autonomous Region, and approximately 220,000 yuan worth of prevention and control medicines to Xingcheng City. In 2021, Haisco (Liaoning) donated disaster relief medicines worth approximately 4.95 million yuan to aid the disaster areas in Henan.

In the rescue efforts for major emergencies such as the earthquakes in Yushu, Qinghai, and Ya'an, Haisco (Tibet) donated a total of over 20 million yuan in urgently needed medicines and funds. During the sudden flood disaster in Jianchang, Huludao, Liaoning in 2024, Haisco (Liaoning) and Haisco (Shenyang) organized charity donations to spread warmth. Haisco (Tibet) invested nearly 10 million yuan for industrial support, innovation space operation, and special education in Shannan City, Tibet, demonstrating the company's commitment through practical actions.

Huludao City Red Cross Society Drug Donation Ceremony
Huludao City Red Cross Society Drug Donation Ceremony
Haisco Medicine Group Liaoning Haisco Pharmaceutical Co., Ltd. Donation Ceremony of Medicines to Huludao Red Cross Society
Haisco Pharmaceutical Love Donation
Haisco Pharmaceutical Love Donation
The COVID-19 pandemic: Haisco Medicine donates to Wuhan with kindness
Haisco is providing aid to Jianchang
Haisco is providing aid to Jianchang
Haisco Medicine Group Liaoning Haisco Pharmaceutical Co., Ltd. Donation Ceremony of Medicines to Huludao Red Cross Society
Strive with a determined heart, walk alongside life
Strive with a determined heart, walk alongside life
Join us in our long-term growth, supporting the health industry, and achieving sustainable investment value.

Contact Us

Haisco Group's Official WeChat Account

Haisco Investor Relations WeChat Account

Haisco Raw Materials Procurement Inquiries

News
Innovation
Pipeline R&D Platforms
Products
Product List Product Topics Pharmacovigilance
Investors
Stock Information Public Announcements Market Data Q&A Investor Hotline
Join Us
Talent Philosophy Careers
About Haisco
About Us Business Presence
Contact Us

Contact Number

+86-028-67250666 (Corporate Services) +86-028-67250620 (Business Development and Cooperation Division) +86-028-67250551 (Investor Hotline)

COPYRIGHT 2026 @ HAISCO Pharmaceutical Group Co., Ltd.

Zang ICP Registration No. 20000012-1 Shu ICP Registration No. 16033962-2Shu ICP No. 16033962-3 The Tibetan public network security registration number is 54222102000053.(Tibetan)-Non-operational-2019-0003

Pharmacovigilance Statement Privacy